X4 Pharmaceuticals Inc (NASDAQ:XFOR) shares traded unchanged at $1.47 on Wall Street last session.
XFOR stock price is now 48.64% away from the 50-day moving average and 31.82% away from the 200-day moving average. The market capitalization of the company currently stands at $246.87M.
With the price target reduced from $3 to $1, B. Riley Securities Downgraded its rating from Buy to Neutral for X4 Pharmaceuticals Inc (NASDAQ: XFOR). , while ‘Cantor Fitzgerald’ rates the stock as ‘Overweight’
In other news, Mostafa Adam S., Chief Financial Officer sold 52,500 shares of the company’s stock on Mar 11 ’24. The stock was sold for $46,347 at an average price of $0.88. Upon completion of the transaction, the Chief Financial Officer now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 11 ’24, President and CEO Ragan Paula sold 49,678 shares of the business’s stock. A total of $43,856 was realized by selling the stock at an average price of $0.88. This leaves the insider owning 765,068 shares of the company worth $1.12 million. A total of 27.41% of the company’s stock is owned by insiders.
During the past 12 months, X4 Pharmaceuticals Inc has had a low of $0.57 and a high of $2.58. As of last week, the company has a debt-to-equity ratio of 1.14, a current ratio of 5.34, and a quick ratio of 5.34. The fifty day moving average price for XFOR is $0.9891 and a two-hundred day moving average price translates $1.1152 for the stock.
The latest earnings results from X4 Pharmaceuticals Inc (NASDAQ: XFOR) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at -$0.1, beating analysts’ expectations of -$0.15 by 0.05. This compares to $0.03 EPS in the same period last year. The company reported revenue of $25.2 million for the quarter, compared to $25.58 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -1.48 percent.
X4 Pharmaceuticals Inc(XFOR) Company Profile
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
